/

ENTX

Entera Bio Ltd.Closed

2.49−0.16 −6.04%USD

NasdaqCM · as of Oct 13, 16:00 ET · 15m delayAfter hours 2.50 +0.40%

Open

2.65

Prev close

2.65

Day range

2.442.65

52-week range

0.91004.20

Volume

754.97K0.40×

Mkt cap

432.85M

P/E ttm

—

Fwd P/E

-4.53

EPS ttm

-0.3600

Div yield

0.00%

Earnings

—

From 52w high

−40.71%

Price Chart

Yahoo Finance · delayed

ENTXOct 13, 2026O 2.65H 2.65L 2.43C 2.49−0.16 (−6.04%)Vol 755.00K

SMA 502.89
SMA 2001.83

1Y change −7.78% since Oct 13, 2025 close539 bars loadedTimes in America/New_YorkDraw from the left toolbar · click a drawing to edit · right-click for alerts and export

ENTX Entera Bio Ltd. · Last Guard Finance

DES

Key Statistics

Yahoo Finance

Performance

1 week: −1.58%
1 month: −12.32%
3 months: +53.70%
6 months: +120.35%
Year to date: +28.35%
1 year: −7.78%

Valuation & ownership

Market cap: 432.85M
Enterprise value: 420.24M
P/E (ttm): —
Forward P/E: -4.53
PEG ratio: —
Price / book: 16.94
Price / sales (ttm): —
EV / EBITDA: -29.25
EPS (ttm): -0.3600
EPS (forward): -0.5500
Beta (5y monthly): 1.41
Dividend yield: 0.00%
Payout ratio: —
Shares outstanding: 173.83M
Float: 126.47M
Short % of float: 1.44%
Short ratio (days): 5.80
Held by insiders: 5.47%
Held by institutions: 34.11%
Avg volume (3m): 1.88M
50-day average: 2.90
200-day average: 1.82
52-week change: −7.78%
S&P 500 52-week: +17.03%

Technicals (daily)

RSI (14): 37.9
vs 50-day SMA: −13.92%
vs 200-day SMA: +36.33%
50 / 200-day trend: ▲ 50 above 200
MACD vs signal: ▼ below
ATR (14) % of price: 7.62%
Realised vol (20d, ann.): 61.7%
From 52-week high: −40.71%
From 52-week low: +173.63%

ANR

Analyst Consensus

4 analysts

Consensus

Strong buy

1.00 on a 1 (strong buy) – 5 (sell) scale

Mean target

9.75

+291.57% implied

Low 9.00Median 9.50High 11.00

Recommendation trend

Now5 / 0 / 0
1m ago5 / 0 / 0

Buy / hold / sell counts

Recent actions

DES

About Entera Bio Ltd.

Yahoo Finance profile

Entera Bio Ltd., a clinical stage company, engages in the development of oral peptides and protein replacement therapies in Israel and internationally. It develops EB613, an oral teriparatide, which completed the Phase II clinical trial for the treatment of osteoporosis and Phase I clinical trial for the treatment of stress fractures. The company is also involved in the development of EB612, a tablet peptide replacement therapy, which is in Phase I clinical trial for the treatment of hypoparathyroidism; EB618, a GLP-1/glucagon dual agonist peptide, which is in Phase I clinical trial for the treatment of obesity, metabolic, and fibrotic disorders; and GLP-2 which is in Phase I clinical trial for the treatment of short bowel syndrome and disorders related to mucosal inflammation and nutrient malabsorption. It has a collaboration agreement with OPKO Biologics, Inc for the preclinical and clinical development of LA-PTH and oral dual agonist GLP-1/glucagon peptide. The company was incorporated in 2009 and is based in Jerusalem, Israel.

Sector: Healthcare
Industry: Biotechnology
Employees: 20
Headquarters: Jerusalem, Israel
Website: enterabio.com
Officers: Ms. Miranda J. Toledano M.B.A. CEO & Director
Dr. Hillel Galitzer M.B.A., Ph.D. Chief Operating Officer
Dr. Gregory Burshtein Ph.D. Chief of Research & Development

SEAS

Seasonality · ENTX

2018–2026 · monthly returns

Strongest month Mar +24.58%Weakest month Aug −11.19%Averages use completed years only. Past seasonality doesn't predict future returns.

Year	Jan	Feb	Mar	Apr	May	Jun	Jul	Aug	Sep	Oct	Nov	Dec	Year
2026	-29.4	1.5	-20.1	7.2	13.4	31.1	68.9	-1.3	-1.4	-14.4			+28.4%
2025	3.3	-15.5	-8.1	27.6	-15.0	3.0	1.6	0.0	-0.5	51.6	-18.2	-18.5	−8.5%
2024	40.0	63.7	21.5	17.4	14.8	-18.2	-12.5	3.7	13.8	-4.7	-9.4	29.3	+253.3%
2023	25.8	-2.4	29.5	-33.6	3.0	6.3	-5.9	-13.0	5.1	-5.5	3.6	-15.5	−17.8%
2022	-18.7	-7.0	34.7	-14.6	-12.2	-38.1	45.9	-30.4	-23.0	-24.7	-13.3	7.5	−74.1%
2021	35.2	13.7	129.5	-12.1	-3.6	85.1	-14.0	-5.1	-3.5	-9.6	-21.6	-15.7	+160.6%
2020	47.2	-0.3	-34.5	10.8	-15.8	-4.2	-8.2	-24.3	-3.1	-16.1	18.3	-12.2	−49.5%
2019	31.1	8.7	-0.6	1.7	-21.6	-0.6	-4.7	-20.5	-4.2	-2.4	-7.4	-4.9	−29.8%
2018							-14.3	0.0	7.6	-1.9	-6.8	-42.6	−51.6%

INSD

Insider Activity · ENTX

Market-wide insider buying →Congress trades →SEC Form 4 filings via Yahoo Finance

Buys, 6 months

0 shares

Sells, 6 months

— shares

Net shares

Net change in insider shares

—

Date	Insider	Transaction	Shares	Value
Aug 6, 2026	Taitel HayaDirector	Stock Award(Grant) at price 0.00 per share.	20.8K	—
Aug 6, 2026	Rubin Steven DanielDirector	Stock Award(Grant) at price 0.00 per share.	19.1K	—
Aug 6, 2026	Germano Geno JDirector	Stock Award(Grant) at price 0.00 per share.	25K	—
Aug 6, 2026	Ellis SeanDirector	Stock Award(Grant) at price 0.00 per share.	20K	—
Aug 6, 2026	Malca YonatanDirector	Stock Award(Grant) at price 0.00 per share.	22.8K	—
Jul 13, 2026	Toledano Miranda JayneChief Executive Officer	Stock Award(Grant) at price 0.00 per share.	420.6K	—
May 6, 2026	Burshtein GregoryOfficer	Stock Award(Grant) at price 0.00 per share.	87.6K	—
May 6, 2026	Galitzer Hillel M.D.Chief Operating Officer	Stock Award(Grant) at price 0.00 per share.	73K	—
May 6, 2026	Yaacov-Garbeli Dana CpaChief Financial Officer	Stock Award(Grant) at price 0.00 per share.	58.4K	—
Mar 8, 2026	Germano Geno JDirector	Purchase at price 1.30 per share.	20K	$26.00K
Mar 4, 2026	Ellis SeanDirector	Purchase at price 1.23 per share.	10K	$12.30K
Feb 11, 2026	Rubin Steven DanielDirector	Purchase at price 1.49 per share.	5K	$7.45K
Feb 9, 2026	Germano Geno JDirector	Purchase at price 1.49 per share.	20K	$29.80K
Feb 9, 2026	Taitel HayaDirector	Purchase at price 1.48 per share.	7.5K	$11.10K
Feb 8, 2026	Rubin Steven DanielDirector	Purchase at price 1.20 per share.	10K	$12.00K
Feb 8, 2026	Ellis SeanDirector	Purchase at price 1.24 per share.	18K	$22.32K
Dec 30, 2025	Taitel HayaDirector	Stock Award(Grant) at price 0.00 per share.	26.3K	—
Dec 30, 2025	Lieberman Gerald MDirector	Stock Award(Grant) at price 0.00 per share.	38.3K	—
Dec 30, 2025	Ostrov Gerald MDirector	Stock Award(Grant) at price 0.00 per share.	28.7K	—
Dec 30, 2025	Ellis SeanDirector	Stock Award(Grant) at price 0.00 per share.	25.4K	—

13F

Investors Holding ENTX

latest 13F filings of 29 followed managers

Investors holding ENTX
Investor	Value	Of portfolio	Shares	Change	Quarter
Renaissance Technologies	$652.9K	0.00%	368.85K	−22%	Q2 2026

From each investor's quarterly 13F filing with the SEC: positions at the quarter's end, reported up to 45 days later. All investors

ENTX

Price Chart

Keyboard shortcuts & functions

Anywhere

Command line

Charts (click the chart first)

Function codes

ENTX

Price Chart

Key Statistics

Performance

Valuation & ownership

Technicals (daily)

Analyst Consensus

About Entera Bio Ltd.

Seasonality · ENTX

Insider Activity · ENTX

Congress Trades · ENTX

Investors Holding ENTX

Investors Holding ENTX

Congress Trades · ENTX

Insider Activity · ENTX

Seasonality · ENTX

Key Statistics

Performance

Valuation & ownership

Technicals (daily)

Analyst Consensus

About Entera Bio Ltd.

Financial Snapshot

Earnings & Dividends

News